The company is significantly advanced its development of a novel therapy for amyloid heart disease, leveraging Attruby. Initial clinical information reveals promising improvements for individuals suffering with the https://bridgebio577472.digitollblog.com/42062986/firm-progresses-cardiac-amyloidosis-treatment-through-the-therapy